1692 related articles for article (PubMed ID: 10810803)
21. Left ventricular outflow tract obstruction and sudden death risk in patients with hypertrophic cardiomyopathy.
Elliott PM; Gimeno JR; Tomé MT; Shah J; Ward D; Thaman R; Mogensen J; McKenna WJ
Eur Heart J; 2006 Aug; 27(16):1933-41. PubMed ID: 16754630
[TBL] [Abstract][Full Text] [Related]
22. Effect of implantable cardioverter-defibrillator on left ventricular ejection fraction in patients with idiopathic dilated cardiomyopathy.
Schaer B; Theuns DA; Sticherling C; Szili-Torok T; Osswald S; Jordaens L
Am J Cardiol; 2010 Dec; 106(11):1640-5. PubMed ID: 21094367
[TBL] [Abstract][Full Text] [Related]
23. Death without prior appropriate implantable cardioverter-defibrillator therapy: a competing risk study.
Koller MT; Schaer B; Wolbers M; Sticherling C; Bucher HC; Osswald S
Circulation; 2008 Apr; 117(15):1918-26. PubMed ID: 18391108
[TBL] [Abstract][Full Text] [Related]
24. Interaction of implantable defibrillator therapy with angiotensin-converting enzyme deletion/insertion polymorphism.
Bedi MS; Postava LA; Murali S; Macgowan GA; Mathier M; McNamara DM; London B
J Cardiovasc Electrophysiol; 2004 Oct; 15(10):1162-6. PubMed ID: 15485441
[TBL] [Abstract][Full Text] [Related]
25. Implantable cardioverter-defibrillator in patients with hypertrophic cardiomyopathy: efficacy and complications of the therapy in long-term follow-up.
Syska P; Przybylski A; Chojnowska L; Lewandowski M; Sterliński M; Maciag A; Gepner K; Pytkowski M; Kowalik I; Maczyńska-Mazuruk R; Ruzyłło W; Szwed H
J Cardiovasc Electrophysiol; 2010 Aug; 21(8):883-9. PubMed ID: 20132378
[TBL] [Abstract][Full Text] [Related]
26. [The natural history of dilated cardiomyopathy: a review of the Heart Muscle Disease Registry of Trieste].
Di Lenarda A; Pinamonti B; Mestroni L; Salvi A; Sabbadini G; Gregori D; Perkan A; Zecchin M; Carniel E; Bussani R; Silvestri F; Morgera T; Camerini F; Sinagra G;
Ital Heart J Suppl; 2004 Apr; 5(4):253-66. PubMed ID: 15346692
[TBL] [Abstract][Full Text] [Related]
27. Comparison of ventricular arrhythmia burden, therapeutic interventions, and survival, in patients < 75 and patients >or= 75 years of age treated with implantable cardioverter defibrillators.
Ermis C; Zhu AX; Vanheel L; Sakaguchi RN; Lurie KG; Lu F; Benditt DG
Europace; 2007 May; 9(5):270-4. PubMed ID: 17371804
[TBL] [Abstract][Full Text] [Related]
28. Life expectancy gains and cost-effectiveness of implantable cardioverter/defibrillators for the primary prevention of sudden cardiac death in patients with hypertrophic cardiomyopathy.
You JJ; Woo A; Ko DT; Cameron DA; Mihailovic A; Krahn M
Am Heart J; 2007 Nov; 154(5):899-907. PubMed ID: 17967596
[TBL] [Abstract][Full Text] [Related]
29. Implantable cardioverter defibrillator therapy: ten years experience in a medical center.
Chen TE; Wang CC; Chang SH; Yeh SJ; Wu D
Chang Gung Med J; 2008; 31(1):81-90. PubMed ID: 18419057
[TBL] [Abstract][Full Text] [Related]
30. Efficacy of implantable cardioverter-defibrillators for the prevention of sudden death in patients with hypertrophic cardiomyopathy.
Maron BJ; Shen WK; Link MS; Epstein AE; Almquist AK; Daubert JP; Bardy GH; Favale S; Rea RF; Boriani G; Estes NA; Spirito P
N Engl J Med; 2000 Feb; 342(6):365-73. PubMed ID: 10666426
[TBL] [Abstract][Full Text] [Related]
31. Effect of concomitant antiarrhythmic therapy on survival in patients with implantable cardioverter defibrillators.
Ho AT; Pai SM; Timothy P; Pai RG
Pacing Clin Electrophysiol; 2005 Jul; 28(7):647-53. PubMed ID: 16008799
[TBL] [Abstract][Full Text] [Related]
32. Prediction of appropriate defibrillator therapy in heart failure patients treated with cardiac resynchronization therapy.
Soliman OI; Theuns DA; van Dalen BM; Vletter WB; Nemes A; Jordaens LJ; Balk AH; Ten Cate FJ; Geleijnse ML
Am J Cardiol; 2010 Jan; 105(1):105-11. PubMed ID: 20102900
[TBL] [Abstract][Full Text] [Related]
33. Enhanced detection of arrhythmia vulnerability using T wave alternans, left ventricular ejection fraction, and programmed ventricular stimulation: a prospective study in subjects with chronic ischemic heart disease.
Rashba EJ; Osman AF; Macmurdy K; Kirk MM; Sarang SE; Peters RW; Shorofsky SR; Gold MR
J Cardiovasc Electrophysiol; 2004 Feb; 15(2):170-6. PubMed ID: 15028046
[TBL] [Abstract][Full Text] [Related]
34. [Implantable cardioverter-defibrillators in patients resuscitated from sudden death and in patients with sustained refractory ventricular tachycardia].
Adragão P; Parreira L; Neves J; Morgado F; Abecassis M; Almeida M; Martins D; Bonhorst D; Seabra-Gomes R
Rev Port Cardiol; 1996 Mar; 15(3):195-206, 179, 181. PubMed ID: 8634168
[TBL] [Abstract][Full Text] [Related]
35. Nonsustained ventricular tachycardia as a predictor for sudden death in patients with idiopathic dilated cardiomyopathy. The role of amiodarone treatment.
Castelli G; Ciaccheri M; Cecchi F; Troiani V; Nannini M; Marconi P; Olivotto J; Montereggi A; Dolara A
G Ital Cardiol; 1999 May; 29(5):514-23. PubMed ID: 10367218
[TBL] [Abstract][Full Text] [Related]
36. [Short-term and long-term outcome of left heart function after cardioverter defibrillator implantation].
Takeichi K; Kasanuki H; Ohnishi S; Endoh Y; Hosoda S
J Cardiol; 1996 Nov; 28(5):277-86. PubMed ID: 8953401
[TBL] [Abstract][Full Text] [Related]
37. Benefit of primary prevention implantable cardioverter-defibrillators in the setting of chronic kidney disease: a decision model analysis.
Amin MS; Fox AD; Kalahasty G; Shepard RK; Wood MA; Ellenbogen KA
J Cardiovasc Electrophysiol; 2008 Dec; 19(12):1275-80. PubMed ID: 18662180
[TBL] [Abstract][Full Text] [Related]
38. Prognostic role of post-infarction C-reactive protein in patients undergoing implantation of cardioverter-defibrillators: design of the C-reactive protein Assessment after Myocardial Infarction to GUide Implantation of DEfibrillator (CAMI GUIDE) study.
Bellocci F; Biasucci LM; Gensini GF; Padeletti L; Raviele A; Santini M; Giubilato G; Landolina M; Biondi-Zoccai G; Raciti G; Sassara M; Castro A; Kheir A; Crea F
J Cardiovasc Med (Hagerstown); 2007 Apr; 8(4):293-9. PubMed ID: 17413310
[TBL] [Abstract][Full Text] [Related]
39. Arrhythmia risk stratification with regard to prophylactic implantable defibrillator therapy in patients with dilated cardiomyopathy. Results of MACAS, DEFINITE, and SCD-HeFT.
Grimm W; Alter P; Maisch B
Herz; 2004 May; 29(3):348-52. PubMed ID: 15167963
[TBL] [Abstract][Full Text] [Related]
40. Predictors of appropriate defibrillator therapy among patients with an implantable defibrillator that delivers cardiac resynchronization therapy.
Desai AD; Burke MC; Hong TE; Kim S; Salem Y; Yong PG; Knight BP
J Cardiovasc Electrophysiol; 2006 May; 17(5):486-90. PubMed ID: 16684019
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
